INT80790

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1999
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 22
Total Number 23
Disease Relevance 4.92
Pain Relevance 12.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Flvcr2) transmembrane transport (Flvcr2)
Anatomy Link Frequency
hippocampus 3
frontal cortex 3
brain 2
substantia nigra 2
striatum 1
Flvcr2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Glutamate 163 100.00 Very High Very High Very High
Dopamine 117 100.00 Very High Very High Very High
Nerve growth factor 44 100.00 Very High Very High Very High
Substantia nigra 6 100.00 Very High Very High Very High
Ventral tegmentum 3 100.00 Very High Very High Very High
Kinase C 15 99.98 Very High Very High Very High
gABA 95 99.84 Very High Very High Very High
cocaine 36 99.78 Very High Very High Very High
withdrawal 16 99.56 Very High Very High Very High
monoamine 23 98.56 Very High Very High Very High
Disease Link Frequency Relevance Heat
Recurrence 3 98.80 Very High Very High Very High
Apoptosis 23 98.40 Very High Very High Very High
Convulsion 442 97.68 Very High Very High Very High
Syndrome 80 97.40 Very High Very High Very High
Urological Neuroanatomy 13 95.84 Very High Very High Very High
Neurodegenerative Disease 16 95.72 Very High Very High Very High
Death 18 92.84 High High
Attention Deficit Hyperactivity Disorder 380 92.24 High High
Nicotine Addiction 2 83.64 Quite High
Epilepsy 190 81.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Monoamine transporter expression was differentially altered by cocaine; dopamine transporter mRNA levels in the ventral tegmental area, but not in the substantia nigra, were increased following withdrawal from cocaine, suggesting a role for the upregulated mesolimbic dopamine transporter in the mechanisms underlying relapse to cocaine taking.
Positive_regulation (upregulated) of transporter in substantia nigra associated with ventral tegmentum, dopamine, substantia nigra, withdrawal, recurrence, cocaine and monoamine
1) Confidence 0.45 Published 2000 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11072100 Disease Relevance 0.10 Pain Relevance 1.35
Monoamine transporter expression was differentially altered by cocaine; dopamine transporter mRNA levels in the ventral tegmental area, but not in the substantia nigra, were increased following withdrawal from cocaine, suggesting a role for the upregulated mesolimbic dopamine transporter in the mechanisms underlying relapse to cocaine taking.
Positive_regulation (increased) of transporter in substantia nigra associated with ventral tegmentum, dopamine, substantia nigra, withdrawal, recurrence, cocaine and monoamine
2) Confidence 0.45 Published 2000 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11072100 Disease Relevance 0.09 Pain Relevance 1.36
The degree of receptor downregulation, as well as transporter upregulation, became less evident after more prolonged drug administration.
Positive_regulation (upregulation) of transporter
3) Confidence 0.35 Published 2000 Journal Headache Section Body Doc Link 10849027 Disease Relevance 0 Pain Relevance 0
To that end, we studied the uptake of [3H]creatine and its electrically evoked release from superfused rat brain slices as well as the evoked release of endogenously synthesized creatine. [3H]creatine was accumulated in neocortex slices in a Na+-dependent manner, consistent with the involvement of the Na+-dependent SLC6A8 creatine transporter.
Positive_regulation (dependent) of transporter in brain
4) Confidence 0.34 Published 2006 Journal Synapse Section Abstract Doc Link 16715490 Disease Relevance 0 Pain Relevance 0.16
The mu-receptor may manifest, as do other neural markers (e.g., dopamine transporter, dopamine efflux), a biphasic temporal pattern with upregulation during early phases of cocaine withdrawal but a downregulation at later times.
Positive_regulation (upregulation) of transporter in neural associated with dopamine, withdrawal and cocaine
5) Confidence 0.31 Published 2000 Journal Synapse Section Abstract Doc Link 10891866 Disease Relevance 0 Pain Relevance 0.80
Other results indicate that the reduction of exocytotic NE release is independent of L- and N-type VSCC, classical drug/peptide binding sites on VSCC, Na+ channels, alpha2-adrenoceptors, NE transporter, and system L amino acid transporter.
Neg (independent) Positive_regulation (independent) of NE transporter
6) Confidence 0.22 Published 2002 Journal Synapse Section Abstract Doc Link 12112396 Disease Relevance 0 Pain Relevance 0.39
Chronic MTEP also caused a significant decrease in mGlu5 gene expression and a significant increase in dopamine transporter and dopamine D(2)-like receptor binding within the olfactory tubercle.
Positive_regulation (increase) of transporter in olfactory tubercle associated with dopamine
7) Confidence 0.19 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 16014750 Disease Relevance 0.49 Pain Relevance 0.43
Prolonged exposure with milnacipran, however, caused time- and concentration-dependent increases in NE uptake and NE transporter density with no increase in NE transporter mRNA.
Neg (no) Positive_regulation (increase) of transporter
8) Confidence 0.12 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654524 Disease Relevance 0 Pain Relevance 0
Even after denervation of the tail artery (by cutting the postganglionic nerves, Fig. 3(3)) to remove the perivascular terminals (and thus the NE transporter), the responses to phenylephrine were much more enhanced relative to control than those to another ?
Positive_regulation (denervation) of transporter in artery
9) Confidence 0.11 Published 2007 Journal Clin Auton Res Section Body Doc Link PMC1797061 Disease Relevance 0 Pain Relevance 0.15
An important regulatory mechanism of synaptic dopamine (DA) levels is activation of the dopamine transporter (DAT), which is a target for many drugs of abuse, including amphetamine (AMPH). sigma receptors are located in dopaminergic brain areas critical to reinforcement.
Positive_regulation (activation) of transporter in brain associated with dopamine
10) Confidence 0.09 Published 1999 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 10087015 Disease Relevance 0.29 Pain Relevance 0.32
In this model, prolonged exposure to milnacipran appears to increase NE transporter function (Shinkai et al 2005).
Spec (appears) Positive_regulation (increase) of transporter
11) Confidence 0.09 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654524 Disease Relevance 0 Pain Relevance 0.08
Prolonged exposure with milnacipran, however, caused time- and concentration-dependent increases in NE uptake and NE transporter density with no increase in NE transporter mRNA.
Positive_regulation (increases) of transporter
12) Confidence 0.08 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654524 Disease Relevance 0 Pain Relevance 0
Activation of NGF receptors up-regulates several cholinergic-specific genes, such as the high-affinity choline transporter and the acetylcholine synthesizing enzyme ChAT, which share a common gene locus with the vesicular acetylcholine transporter (VAChT) [30-33].
Positive_regulation (Activation) of transporter associated with nerve growth factor
13) Confidence 0.03 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC2826326 Disease Relevance 0.83 Pain Relevance 0.30
M, n = 3), and glycine transporter inhibitor sarcosine (500 ?
Positive_regulation (glycine) of transporter
14) Confidence 0.03 Published 2009 Journal Mol Pain Section Body Doc Link PMC2713213 Disease Relevance 0 Pain Relevance 0.28
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (-) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
15) Confidence 0.02 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.33 Pain Relevance 0.91
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (up) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
16) Confidence 0.02 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.33 Pain Relevance 0.91
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (regulation) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
17) Confidence 0.02 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.33 Pain Relevance 0.91
A possible difference between effects on D3 in prenatal versus adult life is supported by the finding that D3 appears early in murine development and is believed to have an important role in prenatal development.179 D3R-deficient mice also have decreased TH, increased DA transporter mRNAs, and increased DA reuptake,180 which parallel the effects of BPA.
Positive_regulation (increased) of transporter associated with dopamine
18) Confidence 0.02 Published 2009 Journal Schizophrenia Bulletin Section Body Doc Link PMC2643957 Disease Relevance 0.25 Pain Relevance 0.61
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (regulation) of transporter in hippocampus associated with glutamate, gaba, urological neuroanatomy and hippocampus
19) Confidence 0.01 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.33 Pain Relevance 0.91
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (up) of transporter in hippocampus associated with glutamate, gaba, urological neuroanatomy and hippocampus
20) Confidence 0.01 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.33 Pain Relevance 0.91

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox